Literature DB >> 9096915

Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment.

E Astorri1, P Fiorina, G Gavaruzzi, A Astorri, G Magnati.   

Abstract

The aim of this study was to compare, by gated radionuclide angiography, systolic and diastolic ventricular function in insulin-dependent (IDDM) and non-insulin-dependent (NIDDM) diabetic patients without overt cardiovascular disease. The study population consisted of 20 IDDM patients (15 male, 5 female; 40.7 +/- 10.3 years), 14 NIDDM patients (9 male, 5 female; 47.0 +/- 7.5 years) and 12 healthy subjects (7 male, 5 female; 41.5 +/- 6.3 years) as a control (C) group. The duration of diabetes (DD) and glycosylated hemoglobin (HbA1C) levels were significantly higher in the IDDM patients. The ventricular ejection fraction and peak ejection rate (PER) were assessed by gated radionuclide left ventriculography and were similar in three groups, while the peak filling rate (PFR) was lower in the NIDDM patients compared to the IDDM patients (p < 0.05) and controlled healthy subjects (p < 0.01, IDDM = 3.39 +/- 1.14; NIDDM = 2.65 +/- 0.83; C = 3.55 +/- 0.73), the time to PFR was significantly more prolonged in the NIDDM group than in the IDDM (p < 0.05) and C groups (p < 0.05, NIDDM = 162 +/- 26; IDDM = 140 +/- 28; C = 142 +/- 23). The PFR/PER ratio was near the normal value (approximately equal to 1) in the IDDM patients and controlled subjects, while in the NIDDM patients it was reduced (approximately equal to 0.84 +/- 0.18). Seven IDDM and 4 NIDDM patients had borderline signs of cardiovascular autonomic neuropathy, unrelated to DD, HbA1C and scintigraphic parameters. Left ventricular systolic performance was substantially normal and similar in both the IDDM and NIDDM patients. Ventricular diastolic filling was impaired in the NIDDM patients, as shown by the decrease in PFR and in particular in the PFR/PER ratio. Our radionuclide data suggest that the NIDDM patients had a prevalent abnormality of ventricular diastolic performance, with respect to the IDDM patients, although the latter patients had higher DD and HbA1C values.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096915     DOI: 10.1159/000177322

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  19 in total

Review 1.  Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism.

Authors:  Stefania Giuliana Garbossa; Franco Folli
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

Review 2.  Immunotherapy for type 1 diabetes.

Authors:  Davide Frumento; Moufida Ben Nasr; Basset El Essawy; Francesca D'Addio; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  J Endocrinol Invest       Date:  2017-03-04       Impact factor: 4.256

3.  Explaining the increased mortality in type 1 diabetes.

Authors:  Chiara Mameli; Sara Mazzantini; Moufida Ben Nasr; Paolo Fiorina; Andrea E Scaramuzza; Gian Vincenzo Zuccotti
Journal:  World J Diabetes       Date:  2015-07-10

4.  Role of podocyte B7-1 in diabetic nephropathy.

Authors:  Paolo Fiorina; Andrea Vergani; Roberto Bassi; Monika A Niewczas; Mehmet M Altintas; Marcus G Pezzolesi; Francesca D'Addio; Melissa Chin; Sara Tezza; Moufida Ben Nasr; Deborah Mattinzoli; Masami Ikehata; Domenico Corradi; Valerie Schumacher; Lisa Buvall; Chih-Chuan Yu; Jer-Ming Chang; Stefano La Rosa; Giovanna Finzi; Anna Solini; Flavio Vincenti; Maria Pia Rastaldi; Jochen Reiser; Andrzej S Krolewski; Peter H Mundel; Mohamed H Sayegh
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

5.  Human urine-derived stem cells play a novel role in the treatment of STZ-induced diabetic mice.

Authors:  Tianxue Zhao; Deng Luo; Yun Sun; Xin Niu; Yang Wang; Chen Wang; Weiping Jia
Journal:  J Mol Histol       Date:  2018-04-19       Impact factor: 2.611

6.  Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site.

Authors:  Moufida Ben Nasr; Andrea Vergani; James Avruch; Liye Liu; Eirini Kefaloyianni; Francesca D'Addio; Sara Tezza; Domenico Corradi; Roberto Bassi; Alessandro Valderrama-Vasquez; Vera Usuelli; James Kim; Jamil Azzi; Basset El Essawy; James Markmann; Reza Abdi; Paolo Fiorina
Journal:  Acta Diabetol       Date:  2015-03-27       Impact factor: 4.280

7.  Effects of restoring normoglycemia in type 1 diabetes on inflammatory profile and renal extracellular matrix structure after simultaneous pancreas and kidney transplantation.

Authors:  Trine Marita Reine; Ingrid Benedicte Moss Kolseth; Astri Jeanette Meen; Jørn Petter Lindahl; Trond Geir Jenssen; Finn Per Reinholt; Joseph Zaia; Chun Shao; Anders Hartmann; Svein Olav Kolset
Journal:  Diabetes Res Clin Pract       Date:  2014-10-28       Impact factor: 5.602

Review 8.  Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.

Authors:  Hyun Joon Paek; Courtney Kim; Stuart K Williams
Journal:  World J Diabetes       Date:  2014-06-15

9.  Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.

Authors:  Laura Montefusco; Moufida Ben Nasr; Francesca D'Addio; Cristian Loretelli; Antonio Rossi; Ida Pastore; Giuseppe Daniele; Ahmed Abdelsalam; Anna Maestroni; Marco Dell'Acqua; Elio Ippolito; Emma Assi; Vera Usuelli; Andy Joe Seelam; Roberta Maria Fiorina; Enrica Chebat; Paola Morpurgo; Maria Elena Lunati; Andrea Mario Bolla; Giovanna Finzi; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Agostino Riva; Domenico Corradi; Pierachille Santus; Manuela Nebuloni; Franco Folli; Gian Vincenzo Zuccotti; Massimo Galli; Paolo Fiorina
Journal:  Nat Metab       Date:  2021-05-25

Review 10.  Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis.

Authors:  Maurizio Gallieni; Cristina De Salvo; Maria Elena Lunati; Antonio Rossi; Francesca D'Addio; Ida Pastore; Gianmarco Sabiu; Roberta Miglio; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  Acta Diabetol       Date:  2021-03-20       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.